The 98 references in paper K. Smirnov A., V. Dobronravov A., К. Смирнов А., В. Добронравов А. (2014) “ОСТРОЕ ПОВРЕЖДЕНИЕ ПОЧЕК ПРИ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК // ACUTE KIDNEY INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION” / spz:neicon:nefr:y:2014:i:6:p:26-42

1
Passweg JR, Baldomero H. The EBMT activity survey: 1990-
(check this in PDF content)
2
10. Bone Marrow Transplant 2012;47(7):906-923 2. www.wbmt.org
(check this in PDF content)
3
Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med1996;125(8):625-633
(check this in PDF content)
4
Mcdonald GB, Hinds MS. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118(4):255-267
(check this in PDF content)
5
George JN, Li X. Thrombotic thrombocytopenic purpurahemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44(2):294-304
(check this in PDF content)
6
Nash RA, Pepe MS. Acute Graft-Versus-Host Disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporin and methotrexate Blood1992; 80(7):1838-1845
(check this in PDF content)
7
Meijer E, Boland GJ. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev2003; 16(4): 647-657
(check this in PDF content)
8
Lopes A, Jorge S. Acute kidney injury following HCT: incidence, risk factors and outcome. Bone Marrow transplantation2011; 46(11):1399-1408
(check this in PDF content)
9
Parikh CR, Coca SG. Acute renal failure in hematopoietic cell transplantation. Kidney Int2006;69(3):430-435
(check this in PDF content)
10
Gruss E, Bernis C. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol 1995;15(6):473-479
(check this in PDF content)
11
Weiss AS, Sandmaier BM. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant 2006; 6(1):89-94
(check this in PDF content)
12
Singh N, McNeely J. Kidney complications of hematopoietic stem cell transplantation. AJKD2013;61(5):809-821
(check this in PDF content)
13
Shimoi T, Ando M. The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT. Bone Marrow Transplantation 2013;48(1):80-84
(check this in PDF content)
14
Hingorani SR, Guthrie K, Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int 2005;67(1):272-277
(check this in PDF content)
15
Zager RA, O’Quigley J. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989;13(3):210–216
(check this in PDF content)
16
Zager RA. Acute renal failure in the setting of bone marrow transplantation. Kidney Int1994;46(5):1443-1458
(check this in PDF content)
17
Parikh CR, McSweeney PA. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 2002; 62(2):566-573
(check this in PDF content)
18
Gooley TA, Chien JW. Reduced mortality after allogeneic hematopoietic cell transplantation. N Engl J Med 2010;363(22):2091
(check this in PDF content)
19
Helal I, Byzun A. Acute renal failure following allogeneic hematopoietic cell transplantation: incidence, outcome and risk factors. Saudi J Kidney Dis Transpl 2011;22(3): 437-443
(check this in PDF content)
20
Humphreys BD, Soiffer RJ. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 2005;16(1):151-161
(check this in PDF content)
21
Parikh CR, Sandmaier BM. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol2004;15(7):1868-1876
(check this in PDF content)
22
Parikh CR, Schrier RW. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 2005;45(3):502-509
(check this in PDF content)
23
Gale RP, Horowitz MM. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120(8):646–652
(check this in PDF content)
24
Parikh CR, McSweeney P. Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int2005; 67(5):1999–2005
(check this in PDF content)
25
Hahn T, Rondeau C. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 2003; 32(4):405–410
(check this in PDF content)
26
Pallera AM, Schwartzberg LS. Managing the toxicity of hematopoietic stem cell transplant. J Support Oncol 2004; 2(3):223-247
(check this in PDF content)
27
EBMT Handbook: EBMT-ESH Handbook on Haemopoietic Stem Cell Transplantation, 2012;221-223
(check this in PDF content)
28
Calne RY, White DJ. Cyclosporin A in patients receiving renal allografts from cadaver donors Lancet 1978;2(8104-8105):1323-1327
(check this in PDF content)
29
Powles RL, Clink HM Cyclosporin A to prevent graft-versushost disease in man after allogeneic bone-marrow transplantationLancet 1980;1(8164):327–329
(check this in PDF content)
30
Смирнов А.В. Лечение гломерулопатий циклоспорином: правильный подход с неверным обоснованием. Нефрология, 2010;14(4):9-22 [Smirnov A.V. Lechenie glomerulopatii` tciclosporinom: pravil`ny`i` podhod s neverny`m obosnovaniem. Nefrologiia, 2010;14(4):9-22]
(check this in PDF content)
31
Shaw KT, Ho AM Immunosuppressive drugs prevent a rapid dephosphoryla- tion of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995;92(24):11205–11209
(check this in PDF content)
32
Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 2007;293(1):F2–F9
(check this in PDF content)
33
Bobadilla NA, Gamba G. Role of NO in cyclosporin nephrotoxicity: effects of chronic NO inhibition and NO synthases gene expression. Am J Physiol Renal Physiol 1998;274(4):F791–F798
(check this in PDF content)
34
Kon V, Sugiura M, Role of endothelin in cyclosporineinduced glomerular dysfunction. Kidney Int 1990;37(6):1487–1491
(check this in PDF content)
35
Perico N, Benigni A. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. Am J Physiol Renal Fluid Electrolyte Physiol 1986; 251(4): F581– F587
(check this in PDF content)
36
Perico N, Benigni A. Acute cyclosporine A nephrotoxicity in rats: which role for renin- angiotensin system and glomerular prostaglandins? Clin Nephrol 1986;25(1):S83–S88
(check this in PDF content)
37
Diederich D, Yang Z. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 1992;2(8):1291–1297
(check this in PDF content)
38
Pichler RH, Franceschini N. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995;6(4):1186–1196
(check this in PDF content)
39
Shihab FS, Bennett WM. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine ne- phropathy. Kidney Int 1997.52(3):660–673
(check this in PDF content)
40
Lopez-Ongil S, Saura M. Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 1996;271(3):H1072–H1078
(check this in PDF content)
41
Zhong Z, Arteel GE. Cyclosporin A increases hypoxia and free radical production in rat kidneys: pre- vention by dietary glycine. Am J Physiol Renal Physiol 1998;275(4): F595– F604
(check this in PDF content)
42
Zhong Z, Connor HD. Dietary glycine and renal denervation prevents cyclosporin A-induced hydroxyl radical production in rat kidney. Mol Pharmacol 1999;561(3):455– 463
(check this in PDF content)
43
Feria I, Pichardo I. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003;63(1):43–52
(check this in PDF content)
44
Ling H, Li X. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003;14(2): 377–388
(check this in PDF content)
45
Verburgh CA, Vermeij CG. Haemolytic uraemic syndrome following bone marrow transplantation: Case report and review of the literature. Nephrol Dial Transplant 1996;11(7):1332-1337
(check this in PDF content)
46
Holler E, Kolb HJ. Microangiopathy in patients on cyclosponne prophylaxis who developed acute graft-versus- host disease after HLA-identical bone marrow transplantation. Blood 1989; 73(7):2018-2024
(check this in PDF content)
47
Yoshinobu Kanda, Rie Hyo. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol 2006;81(11):838-844
(check this in PDF content)
48
Ruutu T, Niederwieser D. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow transplantation (EBMT). Bone Marrow Transplantation 1997;19(8):759-764
(check this in PDF content)
49
Jankauskiene A, Druskis V. Cyclosporine nephrotoxicity: associated allograft dysfunction at low through concentration. Clin Nephrol 2001;56(6):S27-S29
(check this in PDF content)
50
Rex JH, BennettJE. A randomized trial compareing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia: Candidemia Study Group and the National Institute. N Engl J Med 1994;331(20):1325–1330
(check this in PDF content)
51
Bates DW, Su L. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32(5): 686–693
(check this in PDF content)
52
Wingard JR, Beals SU. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987; 2(2):175–181
(check this in PDF content)
53
Karabinis A, Hill C. Risk factors for candidemia in cancer patients: a case–control study. J Clin Microbiol 1988; 26(3):429–432
(check this in PDF content)
54
Sable CA, Donowitz GR. Infection in bone marrow transplant recipients. Clin Infect Dis 1994;18(3): 273–281
(check this in PDF content)
55
Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990;12(6):1147–1201
(check this in PDF content)
56
Goodman JL, Winston DJ. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326(13):845–851
(check this in PDF content)
57
Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemoter 2002;49 [Suppl 1]: 7–10
(check this in PDF content)
58
Brajtburg J, Bolard J. Carrier effects on biological activity of Amphotericin B. Clin Microbiol Rev1996;9(4):512–31
(check this in PDF content)
59
R. Laniado-Labor ́ın, M.N. Cabrales-Vargas. Amphotericin B: side effects and toxicity Rev Iberoam Micol. 2009;26(4):223–227
(check this in PDF content)
60
Wingard JR, Kubilis P. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clinical Infectious Disease1999; 29(6):1402-1407
(check this in PDF content)
61
Deray G. Amphotericin B nephrotoxicity. Journal of antimicrobial chemotherapy2002;49[Suppl 1]:37-41
(check this in PDF content)
62
Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988;148(11):2389-2394
(check this in PDF content)
63
Heidemann HT, Gerkens JF. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983;75(3):476-481
(check this in PDF content)
64
Luber AD, MaaL, Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999; 43(2):267–271
(check this in PDF content)
65
Shulman H, Striker G. Nephrotoxicity of cyclosporinA after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med 1981;305(23):1392-1395
(check this in PDF content)
66
Ohnishi A, Ohnishi T, Sodium status influences chronic Amphotericin B nephrotoxicity in rats. Antimicrob Agents Chemother 1989; 33(8):1222–1227
(check this in PDF content)
67
Gerkens JF, Branch RA The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther 1980; 214(2):306–311
(check this in PDF content)
68
KDIGO AKI Guideline, vol2, issue1, 2012
(check this in PDF content)
69
Craig M, Cumpston AD. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantational unit. Bone Marrow Transplantation 2007;39(8):477-482
(check this in PDF content)
70
Maschmeyer G, Ljungman P. Infections in hematopoietic stem cell transplant recipients. A. Safdar (ed.), Principles and Practice of Cancer Infectious Diseases, Current Clinical Oncology,2011
(check this in PDF content)
71
Kruger WH, Kiefer T. Aminoglycoside-free interventional antibiotic management in patients undergoing haemopoietic stem cell transplantation. GMS Krankenhhyg Interdiszip. 2010; 5(2)
(check this in PDF content)
72
Martinez-Salgado C, Lopez-Hernandez FJ. Glomerular nephrotoxicity of aminoglycosides. Toxicology and applied pharmacology 2007;223(1):86-98
(check this in PDF content)
73
Nagai, J., Takano, M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab. Pharmacokineti2004;19(3):159–170
(check this in PDF content)
74
Shakil S, Khan R. Aminoglycosides versus bacteria-a description of the action, resistance mechanism, and nosocomial battleground. Journal of Biomedical Science 2008;15(1):5–14
(check this in PDF content)
75
Oliveira JFP, Silva CA. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrobial agents and chemotherapy 2009;53(7):2887–2891
(check this in PDF content)
76
Lopez-Novoa JM, Quiros Yaremi. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney International 2011;79(1):33–45
(check this in PDF content)
77
Добронравов В.А. Патофизиология острого повреждения почек (книга “Острое повреждение почек”, в печати, 2014 г [Dobronravov V.A. Patofiziologiia ostrogo povrezhdeniia pochek (kniga “Ostroe povrezhdenie pochek”, v pechati, 2014 g]
(check this in PDF content)
78
King DH. History, pharmacokinetics, and pharmacology of acyclovir. J Am Acad Dermatol. 1988;18(1):176-179
(check this in PDF content)
79
Fyfe JA, Keller PM. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound 9-(2-hydroxyethoxymethyl) guanine. J Biol Chem 1978;253(24):8721-8727
(check this in PDF content)
80
Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980;255(15):7204-7207
(check this in PDF content)
81
Perazella MA. Crystal-induced acute renal failure. Am J Med1999; 106(4):459-465
(check this in PDF content)
82
Gunness P, Alexa K. Acyclovir-induced nephrotoxicity: the role of acyclovir aldehyde metabolite. Transl Res 2011;158(5):290-301
(check this in PDF content)
83
Selzer G, Parker GF. Senecio poisoning exhibiting as chiaris syndrome Am J Pathol 1950;27:885-907
(check this in PDF content)
84
Jacobs P, Miller J L. Fatal veno- occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukemia. S Afr Med J 1979; 55(1): 5-10
(check this in PDF content)
85
Carreras E, Bertz H. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998;92(10):3599–3604
(check this in PDF content)
86
Carreras E, Granena A.Hepatic venoocclusive disease after bone marrow transplantation. Blood Reviews 1993;7(1):43-51
(check this in PDF content)
87
Carreras E. Veno-occlusive disease of the liver after hematopoietic cell transplantation. Eu J Haematol 2000; 64(5):281-291
(check this in PDF content)
88
DeLeve LD, Shulman HM. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease)Semin Liver Dis 2002; 22(1): 27-42
(check this in PDF content)
89
HoVT, LindenE. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Review and update on the use of defibrotide. Semin Thromb Hemost 2007; 33(4):373-388
(check this in PDF content)
90
Carreras E. Early complications after HSCT. The EBMT Handbook revised edition. 2008; 180-197
(check this in PDF content)
91
Fink JC, Cooper MA. Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced “hepatorenal syndrome”. Am Soc Nephrol 1995; 6(6):1655–1660
(check this in PDF content)
92
Sawinski D. The kidney effects of hematopoietic stem cell transplantation. Advances in chronic kidney disease. 2014;21(1):96-105
(check this in PDF content)
93
Kumar S, DeLeve LD. Hepatic Veno-occlusive Disease (Sinusoidal obstruction syndrome) after hematopoietic stem cell transpalntation. Mayo Clin Proc2003;78(5):589-598
(check this in PDF content)
94
Lee SJ, Klein J. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood2007;110(13):4576-4583
(check this in PDF content)
95
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11(12):945-956
(check this in PDF content)
96
Nelson J Chao, Clinical manifestations, diagnosis and grading of acute graft-versus-host disease. UptoDate 2013
(check this in PDF content)
97
Deeg HJ Henslee-Downey PJ. Management of acute graftversus-host disease. Bone Marrow Transplant 1990;6(1): 1-8Copelan EA, Hematopoietic stem cell transplantation. N Engl J Med 2006;354(17):1813-1826
(check this in PDF content)
98
Ball LM, Egeler RM. Acute GVHD: pathogenesis and classification. Bone Marrow Transplantation 2008;41[Suppl 2] S58-S64 100. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol 2003;21(4):149-161 101. Homma CI, Kami M, Graft-versus-host disease of the
(check this in PDF content)